Endra Life Sciences, an Ann Arbor-based developer of ultrasound systems, has signed a collaboration agreement with GE Healthcare to add physiological and molecular imaging capabilities to current ultrasound devices.
“We believe that Endra’s technology has the potential to bring significant new capabilities to ultrasound – which aligns well with GE Healthcare’s mission of broadening access to high-quality, cost-effective health care,” says Brian McEathron, Vice President of GE Healthcare and General Manager for Radiology and Vascular Ultrasound.
McEathron says the technology is being developed to enable existing ultrasound systems to visualize tissue function, composition, and monitor a variety of therapeutic interventions at the point of care. “These capabilities could have broad potential clinical applications, including aiding in a non-invasive diagnosis of fatty liver disease, which affects over 1 billion people around the world,” he says.
Under the terms of the agreement, GE Healthcare will support Endra’s efforts to commercialize the technology, provide equipment and technical advice, and will facilitate introductions to GE Healthcare clinical ultrasound customers.
Endra will give GE Healthcare certain rights of first offer the technology, with respect to manufacturing and licensing rights for the target application.
GE Healthcare is a subsidiary of General Electric, headquartered in Chicago.